Literature DB >> 9660108

Antiglutamatergic therapy in Alzheimer's disease--effects of lamotrigine. Short communication.

S Tekin1, C Aykut-Bingöl, T Tanridağ, S Aktan.   

Abstract

It has been proposed that excitotoxic damage by glutamatergic hyperactivity is responsible for neurodegeneration in Alzheimer's disease. Lamotrigine (LTG) inhibits presynaptic glutamate release and is considered to be effective in treatment of other neurodegenerative disorders by its cerebroprotective properties. We used LTG in 11 patients with the diagnosis of probable Alzheimer's disease. 300 mg/day administration of LTG improved word recognition, naming and depressed mood on Alzheimer Disease Assessment Scale (ADAS).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660108     DOI: 10.1007/s007020050059

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  13 in total

Review 1.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

Review 2.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

3.  Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.

Authors:  W Danysz; C G Parsons; H J Mobius; A Stoffler; G Quack
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Seizures in setting of dementia.

Authors:  Kartik Sivaraaman; Vimala S Vajjala
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 5.  Epileptic seizures in AD patients.

Authors:  A J Larner
Journal:  Neuromolecular Med       Date:  2009-06-26       Impact factor: 3.843

6.  Pharmacological models in Alzheimer's disease research.

Authors:  C Gilles; S Ertlé
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

7.  Clinical utility of adjunctive retigabine in partial onset seizures in adults.

Authors:  Konrad Rejdak; Jarogniew J Luszczki; Barbara Błaszczyk; Roman Chwedorowicz; Stanislaw J Czuczwar
Journal:  Ther Clin Risk Manag       Date:  2012-01-20       Impact factor: 2.423

Review 8.  Medical management of epileptic seizures: challenges and solutions.

Authors:  Anand K Sarma; Nabil Khandker; Lisa Kurczewski; Gretchen M Brophy
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-24       Impact factor: 2.570

9.  Lamotrigine Reduces Inflammatory Response and Ameliorates Executive Function Deterioration in an Alzheimer's-Like Mouse Model.

Authors:  Kexin Wang; Alejandro Fernandez-Escobar; Shuhong Han; Ping Zhu; Jun-Hui Wang; Yu Sun
Journal:  Biomed Res Int       Date:  2016-11-30       Impact factor: 3.411

Review 10.  Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease.

Authors:  Sofia Toniolo; Arjune Sen; Masud Husain
Journal:  Int J Mol Sci       Date:  2020-12-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.